CUE Stock Overview
A clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Cue Biopharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.48 |
52 Week High | US$4.89 |
52 Week Low | US$1.30 |
Beta | 1.99 |
1 Month Change | -14.94% |
3 Month Change | -16.38% |
1 Year Change | -60.95% |
3 Year Change | -89.12% |
5 Year Change | -81.31% |
Change since IPO | -87.27% |
Recent News & Updates
Recent updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Oct 04Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
Aug 26Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates
Aug 10Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%
May 18Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12Cue Biopharma: A First Assessment
May 11Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 19Cue Biopharma: Too Long To Arrive At Topline Trial Data
Feb 23We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer
Jun 10Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth
Jun 07Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients
May 10How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?
Mar 21We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Feb 22Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?
Jan 27Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
Jan 07Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year
Dec 25Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)
Nov 29We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Nov 24Cue Biopharma (CUE) Investor Presentation - Slideshow
Nov 20Shareholder Returns
CUE | US Biotechs | US Market | |
---|---|---|---|
7D | -10.3% | 3.0% | 0.8% |
1Y | -60.9% | 8.3% | 22.5% |
Return vs Industry: CUE underperformed the US Biotechs industry which returned 8.3% over the past year.
Return vs Market: CUE underperformed the US Market which returned 22.5% over the past year.
Price Volatility
CUE volatility | |
---|---|
CUE Average Weekly Movement | 16.2% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CUE's share price has been volatile over the past 3 months.
Volatility Over Time: CUE's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 53 | Dan Passeri | www.cuebiopharma.com |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series.
Cue Biopharma, Inc. Fundamentals Summary
CUE fundamental statistics | |
---|---|
Market cap | US$71.99m |
Earnings (TTM) | -US$49.97m |
Revenue (TTM) | US$7.02m |
10.3x
P/S Ratio-1.4x
P/E RatioIs CUE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CUE income statement (TTM) | |
---|---|
Revenue | US$7.02m |
Cost of Revenue | US$38.91m |
Gross Profit | -US$31.88m |
Other Expenses | US$18.09m |
Earnings | -US$49.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.03 |
Gross Margin | -454.20% |
Net Profit Margin | -711.84% |
Debt/Equity Ratio | 24.0% |
How did CUE perform over the long term?
See historical performance and comparison